About BioAge Labs
12 articles with BioAge Labs
BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest
BioAge Labs, Inc. (“BioAge”), a clinical-stage biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, today announced positive Phase 1b clinical data for BGE-105, a highly selective, potent, orally available small-molecule agonist of the apelin receptor APJ.
BioAge Labs, PTC Therapeutics, Biogen and others highlighted novel mechanisms targeting newer pathways in neurodegenerative diseases at the recent Discovery on Target meeting.
BioAge Labs to Present Data on Novel Brain-Penetrant NLRP3 Inhibitors for Treatment of Neurodegeneration and Brain Aging at Upcoming Conferences
BioAge Labs, Inc. announced that it will present updates on its NLRP3 inhibitor program at two upcoming conferences in the United States, Neurodegeneration Targets and the Inflammasome Therapeutics Summit, and at the BIO-Europe 2022 conference in Leipzig, Germany.
BioAge Partners With Age Labs to Decipher Healthy Longevity Using Samples and Data From a Preeminent Northern European Biobank
BioAge Labs, Inc., a biotechnology company developing therapeutics that target the molecular causes of aging to extend healthy human lifespan, announced that it has initiated a partnership agreement with Age Labs AS, a diagnostic company that develops tests for the early detection of age-related diseases.
BioAge CEO to Lead a Panel Discussion at the BIO 2022 Conference: “Targeting Aging Pathways to Treat Chronic Disease” — June 14, 2022, 11 AM
BioAge Labs, Inc. announced that Kristen Fortney, PhD, CEO and Co-Founder of BioAge, will lead a panel discussion at the BIO International Conference held June 13–16, 2022 in San Diego, California.
BioAge Labs, Inc. announced that BioAge chief business officer Peng Leong, PhD, MBA, has been appointed as the Company’s Head of Brain Aging.
BioAge Developing a Novel Class of Potent NLRP3 Inhibitors With Distinct Structural and Pharmacologic Properties for Inflammatory and Age-Related Diseases
BioAge Labs, Inc. announced that it is developing a family of novel small-molecule NLRP3 inhibitors as therapeutics for inflammatory and age-related diseases.
BioAge Announces First Cohort Dosed in Phase 1b Clinical Trial of the Apelin Receptor Agonist BGE-105, Under Development for Muscle Aging Indications
BioAge Labs, Inc. announced that the first cohort has been dosed in a Phase 1b trial of BGE-105, a highly selective and potent small-molecule agonist of the apelin receptor APJ.
BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.
Nature Paper: BioAge’s Oral Drug Targeting the Aging Immune System Prevents Death From COVID-19 in Aged Mice
BioAge Labs, Inc., a biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, announced that its clinical-stage oral drug BGE-175, which targets age-related immune deficiencies, protects aged mice from lethal infection with SARS-CoV-2, the virus that causes COVID-19.
BioAge Labs, Inc. today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
BioAge Labs, Inc. today announced the appointment of Rekha Hemrajani and Jason Coloma to the company’s board of directors.